Pharmacokinetic profile of the synthetic mu-opioid receptor agonist Dermorphin-IRDye(R)800CW and its feasibility as a biomarker for opioid use disorder
K. S. Samkoe, R. R. Strawbridge, M. R. Spaller, A. A. Pletnev, D. J. Wirth, B. K. Byrd, B. Meng, J. S. Sottosanti, S. C. Davis, J. T. Elliott
This paper develops a fluorescent peptide agonist to measure mu-opioid receptor occupancy in vivo and assesses its potential as a biomarker for opioid use disorder.
bioRxiv · Jun 19, 2023 · PreprintBioengineering